Who are raloxifene HCI and alendronate Na's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raloxifene-hci-and-alendronate-na.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

raloxifene HCI and alendronate Na — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

raloxifene HCI and alendronate Na (raloxifene HCI and alendronate Na) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM) + bisphosphonate combination. Area: Bone health / Osteoporosis.

marketed Selective estrogen receptor modulator (SERM) + bisphosphonate combination Estrogen receptor (raloxifene); osteoclast farnesyl pyrophosphate synthase (alendronate) Bone health / Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

raloxifene HCI and alendronate Na (raloxifene HCI and alendronate Na) — Eli Lilly and Company. This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
raloxifene HCI and alendronate Na TARGET	raloxifene HCI and alendronate Na	Eli Lilly and Company	marketed	Selective estrogen receptor modulator (SERM) + bisphosphonate combination	Estrogen receptor (raloxifene); osteoclast farnesyl pyrophosphate synthase (alendronate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) + bisphosphonate combination class)

Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). raloxifene HCI and alendronate Na — Competitive Intelligence Brief. https://druglandscape.com/ci/raloxifene-hci-and-alendronate-na. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab